B. Findlay

12.7k total citations · 2 hit papers
44 papers, 9.1k citations indexed

About

B. Findlay is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, B. Findlay has authored 44 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in B. Findlay's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Breast Cancer Treatment Studies (9 papers). B. Findlay is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Breast Cancer Treatment Studies (9 papers). B. Findlay collaborates with scholars based in Canada, United States and New Zealand. B. Findlay's co-authors include Richard M. Goldberg, Daniel J. Sargent, Charles S. Fuchs, Roscoe F. Morton, Stephen K. Williamson, Ramesh K. Ramanathan, Frances A. Shepherd, Henry C. Pitot, Lesley Seymour and Dongsheng Tu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

B. Findlay

44 papers receiving 8.8k citations

Hit Papers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer 2003 2026 2010 2018 2005 2003 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
    2005 4.3k citations Frances A. Shepherd, José Rodrigues Pereira et al. New England Journal of Medicine profile →
  2. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
    2003 1.8k citations Richard M. Goldberg, Daniel J. Sargent et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Findlay Canada 25 7.0k 4.8k 1.7k 1.5k 1.0k 44 9.1k
Enrico Cortesi Italy 41 4.7k 0.7× 2.5k 0.5× 1.2k 0.7× 1.5k 1.0× 1.2k 1.2× 266 7.2k
Rodryg Ramlau Poland 43 8.9k 1.3× 9.1k 1.9× 3.1k 1.8× 1.6k 1.1× 815 0.8× 245 12.8k
Otilia Dalesio Netherlands 40 4.4k 0.6× 3.9k 0.8× 1.5k 0.9× 1.0k 0.7× 581 0.6× 104 8.0k
Vladimir Moiseyenko Russia 33 5.6k 0.8× 4.1k 0.9× 1.0k 0.6× 1.3k 0.9× 500 0.5× 142 8.1k
Maciej Krzakowski Poland 43 7.6k 1.1× 6.4k 1.3× 2.2k 1.3× 1.6k 1.1× 426 0.4× 261 11.4k
Derek J. Jonker Canada 34 6.6k 0.9× 2.7k 0.6× 1.9k 1.1× 1.7k 1.1× 1.2k 1.2× 218 8.7k
Bruno Landi France 26 5.9k 0.8× 2.9k 0.6× 1.5k 0.9× 1.5k 1.0× 1.5k 1.5× 70 8.3k
Harry Bleiberg Belgium 40 7.2k 1.0× 4.2k 0.9× 1.7k 1.0× 855 0.6× 1.7k 1.7× 163 10.2k
Alan B. Sandler United States 44 4.5k 0.6× 3.7k 0.8× 2.4k 1.4× 1.0k 0.7× 402 0.4× 109 7.5k
Thomas H. Cartwright United States 25 7.3k 1.0× 3.0k 0.6× 3.4k 2.0× 1.9k 1.3× 2.0k 1.9× 81 11.2k

Countries citing papers authored by B. Findlay

Since Specialization
Citations

This map shows the geographic impact of B. Findlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Findlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Findlay more than expected).

Fields of papers citing papers by B. Findlay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Findlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Findlay. The network helps show where B. Findlay may publish in the future.

Co-authorship network of co-authors of B. Findlay

This figure shows the co-authorship network connecting the top 25 collaborators of B. Findlay. A scholar is included among the top collaborators of B. Findlay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Findlay. B. Findlay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McGarrah, Patrick W., Joleen M. Hubbard, Paul J. Novotny, et al.. (2023). Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control. 30. 2915603095–2915603095. 3 indexed citations
2.
Goodwin, Pamela J., Roanne Segal, Michael Vallis, et al.. (2020). The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. npj Breast Cancer. 6(1). 6–6. 33 indexed citations
3.
Goodwin, Pamela J., Roanne Segal, Michael Vallis, et al.. (2014). Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology. 32(21). 2231–2239. 119 indexed citations
4.
Cigler, Tessa, Dongsheng Tu, Martin J. Yaffe, et al.. (2009). A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Research and Treatment. 120(2). 427–435. 30 indexed citations
5.
Mittmann, Nicole, H. Au, Christopher J. O’Callaghan, et al.. (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. JNCI Journal of the National Cancer Institute. 101(17). 1182–1192. 122 indexed citations
6.
7.
Sargent, Daniel J., Steven R. Alberts, Axel Grothey, et al.. (2007). Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer. 110(3). 670–677. 24 indexed citations
8.
Dy, Grace K., James E. Krook, Erin M. Green, et al.. (2007). Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. Journal of Clinical Oncology. 25(23). 3469–3474. 49 indexed citations
9.
Delaunoit, Thierry, Steven R. Alberts, Daniel J. Sargent, et al.. (2005). Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Annals of Oncology. 16(3). 425–429. 120 indexed citations
10.
Shepherd, Frances A., José Rodrigues Pereira, Tudor–Eliade Ciuleanu, et al.. (2005). Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. New England Journal of Medicine. 353(2). 123–132. 4281 indexed citations breakdown →
11.
Goldberg, Richard M., Daniel J. Sargent, Roscoe F. Morton, et al.. (2004). N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. Journal of Clinical Oncology. 22(14_suppl). 3621–3621. 43 indexed citations
12.
Goldberg, Richard M., Daniel J. Sargent, Roscoe F. Morton, et al.. (2003). A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology. 22(1). 23–30. 1818 indexed citations breakdown →
13.
14.
15.
Hirte, Holger W., Daniel Miller, Katia Tonkin, et al.. (1997). A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma. Gynecologic Oncology. 64(1). 80–87. 19 indexed citations
16.
Latreille, Jean, Francis Laberge, Paul Hoskins, et al.. (1995). Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Supportive Care in Cancer. 3(5). 307–312. 37 indexed citations
17.
Levine, Mark N., Vivien Bramwell, Kathleen I. Pritchard, et al.. (1993). A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. 29(1). 37–43. 18 indexed citations
18.
Bramwell, V., Hakam Abu-Zahra, Andrew Arnold, et al.. (1992). The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. British Journal of Cancer. 65(1). 130–132. 15 indexed citations
19.
Figueredo, A, et al.. (1990). Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study. Cancer. 65(9). 1895–1902. 36 indexed citations
20.
Levine, Mark N., Michael Gent, W M Hryniuk, et al.. (1990). A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.. Journal of Clinical Oncology. 8(7). 1217–1225. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrico Cortesi Breakdown of academic impact, for papers by Rodryg Ramlau Breakdown of academic impact, for papers by Otilia Dalesio Breakdown of academic impact, for papers by Vladimir Moiseyenko Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Derek J. Jonker Breakdown of academic impact, for papers by Bruno Landi Breakdown of academic impact, for papers by Harry Bleiberg Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by Thomas H. Cartwright
Rankless by CCL
2026